News

Fierce Biotech2d
Novartis pens ProFound pact, offering up $750M biobucks per cardiovascular target
Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...
PMLive1d
Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target
Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...
GEN - Genetic Engineering and Biotechnology News1d
Novartis, ProFound Therapeutics Ink Multi-Year Collaboration to Target Cardiovascular Disease Proteins
Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.
Pharmabiz1d
ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease
ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...
The Pharma Letter2d
Novartis inks deal with ProFound on cardio diseases
Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...
Morningstar2d
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease - Morningstar
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease Provided by GlobeNewswire Jun 26, 2025, 10:30 ...